Hemodynamic Response of Rifaximin plus Non-selective ß-blocker versus non-selective ß-blocker monotherapy in Cirrhotic Patients with esophageal varices

Not Applicable

• Conditions: Diseases of the digestive system

• Registration Number: KCT0000788
• Lead Sponsor: Yonsei University, Wonju Severance Christian Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 March 2019

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

1.Liver cirrhosis:diagnosed based on histology or unequivocal clinical, sonographic, and laboratory findings
2.Esophageal varices, F2 or F3
3.Hepatic venous pressure gradient > 12mmHg
4.Informed consent

Exclusion Criteria

1.Shock status requiring vasopressor
2.Active infection, for example Spontaneous bacterial peritonitis
3.Acute renal failure patients of any cause
4.Clinically relevant coronary artery disease(NYHA functional angina classification III/IV),congestive heart failure NYHA III/IV), clinically relevant cardiomyopathy, history of myocardial infarction in the past 12 months
5.Poorly controlled hypertension (BP 150/100mmHg)
6.Hepatocellular carcinoma
7.History of another primary malignancy = 3years
8.Medical or psychological conditions that would not permit the subject to complete thte study or sign informed consent
9.Pregnancy or lactation period
10.Serum creatinine ? 6mg/dL
11.Involvement in the conduct of other study within 30 days
12.Known hypersensitivity to Rifaximin or propranolol
13.Dysarrhythmia, inappropriate for study on investigator's judgment

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hepatic vein pressure gradient(HVPG)

Secondary Outcome Measures

Name	Time	Method
occurence of gastrointestinal bleeding